Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

The β2-adrenergic receptor is a molecular switch for neuroendocrine transdifferentiation of prostate cancer cells.

Braadland PR, Ramberg H, Grytli HH, Urbanucci A, Nielsen HK, Guldvik IJ, Engedal A, Ketola K, Wang W, Svindland A, Mills IG, Bjartell A, Tasken KA.

Mol Cancer Res. 2019 Aug 8. pii: molcanres.0605.2018. doi: 10.1158/1541-7786.MCR-18-0605. [Epub ahead of print]

PMID:
31395667
2.

Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness.

Moen LV, Ramberg H, Zhao S, Grytli HH, Sveen A, Berge V, Skotheim RI, Taskén KA, Skålhegg BS.

Urol Oncol. 2017 Mar;35(3):111.e1-111.e8. doi: 10.1016/j.urolonc.2016.10.002. Epub 2016 Nov 9.

PMID:
27838142
3.

PBX3 is a putative biomarker of aggressive prostate cancer.

Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA.

Int J Cancer. 2016 Oct 15;139(8):1810-20. doi: 10.1002/ijc.30220. Epub 2016 Jun 25.

4.

Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.

Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA.

Oncotarget. 2016 Jan 12;7(2):1878-94. doi: 10.18632/oncotarget.6479.

5.

β-Adrenergic Receptor Signaling in Prostate Cancer.

Braadland PR, Ramberg H, Grytli HH, Taskén KA.

Front Oncol. 2015 Jan 12;4:375. doi: 10.3389/fonc.2014.00375. eCollection 2014. Review.

6.

TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells.

Eide T, Ramberg H, Glackin C, Tindall D, Taskén KA.

Cancer Cell Int. 2013 Jan 31;13(1):4. doi: 10.1186/1475-2867-13-4.

7.

The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy.

Lazarevic B, Hammarström C, Yang J, Ramberg H, Diep LM, Karlsen SJ, Kucuk O, Saatcioglu F, Taskèn KA, Svindland A.

Br J Nutr. 2012 Dec 28;108(12):2138-47. doi: 10.1017/S0007114512000384. Epub 2012 Mar 8.

PMID:
22397815
8.

Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial.

Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H, Moen A, Wessel N, Berg RE, Egge-Jacobsen W, Hammarstrom C, Svindland A, Kucuk O, Saatcioglu F, Taskèn KA, Karlsen SJ.

Nutr Cancer. 2011;63(6):889-98. doi: 10.1080/01635581.2011.582221. Epub 2011 Jun 29.

PMID:
21714686
9.

Regulation of PBX3 expression by androgen and Let-7d in prostate cancer.

Ramberg H, Alshbib A, Berge V, Svindland A, Taskén KA.

Mol Cancer. 2011 May 6;10:50. doi: 10.1186/1476-4598-10-50.

10.

Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.

Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA.

Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.

PMID:
18454446
11.

Androgen dependent regulation of protein kinase A subunits in prostate cancer cells.

Kvissel AK, Ramberg H, Eide T, Svindland A, Skålhegg BS, Taskén KA.

Cell Signal. 2007 Feb;19(2):401-9. Epub 2006 Jul 25.

PMID:
16949795
12.

Formate dehydrogenase in Arabidopsis thaliana: characterization and possible targeting to the chloroplast.

Olson BJ, Skavdahl M, Ramberg H, Osterman JC, Markwell J.

Plant Sci. 2000 Nov 6;159(2):205-212.

PMID:
11074273

Supplemental Content

Loading ...
Support Center